November 20th 2024
Calling it a barrier to care, FDA committees decide to end clozapine REMS.
2023 Annual Psychiatric Times™ World CME Conference
View More
5th Annual International Congress on the Future of Neurology®
View More
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
Patient, Provider, and Caregiver Connection™: Exploring Unmet Needs In Postpartum Depression – Making the Case for Early Detection and Novel Treatments
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
Real Psychiatry 2025
January 17 - 18, 2025
View More
More Than ‘Blue’ After Birth: Managing Diagnosis and Treatment of Post-Partum Depression
View More
Patient, Provider & Caregiver Connection™: Reducing the Burden of Parkinson Disease Psychosis with Personalized Management Plans
View More
Expert Perspectives in the Recognition and Management of Postpartum Depression
View More
Southern California Psychiatry Conference
July 11-12, 2025
Register Now!
SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era
View More
Expert Illustrations & Commentaries™: New Targets for Treatment in Cognitive Impairment in Schizophrenia – The Role of NMDA Receptors and Co-agonists
View More
BURST CME™ Part I: Understanding the Impact of Huntington’s Disease
View More
Burst CME™ Part II: The Evolving Treatment Landscape for Huntington Disease
View More
Clinical ShowCase: Developing a Personalized Treatment Plan for a Patient with Huntington’s Disease Associated Chorea
View More
Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia
View More
Community Practice Connections™: Optimizing the Management of Tardive Dyskinesia—Addressing the Complexity of Care With Targeted Treatment
View More
Key Concepts About Polypharmacy in Psychotic Disorders
August 3rd 2020Clinicians should keep in mind the risk-to-benefit ratio considerations before initiating polypharmacy, especially if they have patients with prescriptions inherited from several sources. Here: A summary of recommendations about the use of polypharmacy in psychotic disorders.
Read More
Pharmacological Management of Violence and Violent Behavior in Psychiatric Settings
February 28th 2020Psychotic violence is associated with primary psychotic disorders such as schizophrenia, schizoaffective disorder, and bipolar disorder. While it may be that psychotic violence is the least common type of violence in inpatient environments, it is also the most treatable.
Read More
Integrating Psychotherapy and Psychopharmacology in the Treatment of Major Depressive Disorder
January 30th 2020Although multiple interventions exist for major depressive disorder (MDD), only partial response is achieved in many patients and recurrence is common. Combining medication and psychotherapy may enable more effective treatment of MDD.
Read More
When Medications Affect More Than the Patient: Opioids and Family Members
December 30th 2019Three studies highlight how important it is that when physicians prescribe opioids there can be significant and even potentially fatal consequences for the family members of those for whom they are being prescribed.
Read More
Psychiatric Adverse Effects of Antibiotics
Nearly all antibiotic agents have been associated with CNS effects. Although uncommon, these events can be severe.
Read More